Frontrunner in Therapies for Complement- Mediated Diseases

Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular deg...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical technology Europe 2023-07, Vol.35 (7), p.11-12
Main Author: Piachaud-Moustakis, Bianca
Format: Article
Language:English
Subjects:
Atrophy
Competition
Disease
Funding
Immune system
Innovations
Laboratories
Macular degeneration
Patients
Pharmaceutical industry
Precision medicine
R&D
Research & development
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 12
container_issue 7
container_start_page 11
container_title Pharmaceutical technology Europe
container_volume 35
creator Piachaud-Moustakis, Bianca
description Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular degeneration (AMD), kidney disease, and various haematological conditions. According to Rafiq Hasan, CEO and managing director at Complement Therapeutics GmbH, "the support of this broad syndicate enables us to generate additional data demonstrating CTx001's unique and differentiated mechanism of action, with the potential to transform the treatment landscape in [GA]" (9). According to the US National Eye Institute (NEI), dry AMD has three stages: early, intermediate, and late, with the disease usually progressing slowly over several years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of complement therapeutics is likely to expand further with the market poised to witness steady growth over the coming years.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2843449646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2843449646</sourcerecordid><originalsourceid>FETCH-proquest_journals_28434496463</originalsourceid><addsrcrecordid>eNqNirEOgjAUADtoIor_0MSZBG1pxRUlLm7spAmPWAJtfa_9fxn8AKdL7m7DsrOuRKFrpXdsTzSV5SoqkbFbi95FTM4Bcut49wY0wQLx0SNv_BJmWMDFgr9gsCbCwO-WwBBQzrajmQmOPx7YqX10zbMI6D8JKPaTT-jW1F-uUkhZK6nEf9cXZsM2Ug</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2843449646</pqid></control><display><type>article</type><title>Frontrunner in Therapies for Complement- Mediated Diseases</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Business Source Ultimate (EBSCOHost)</source><creator>Piachaud-Moustakis, Bianca</creator><creatorcontrib>Piachaud-Moustakis, Bianca</creatorcontrib><description>Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular degeneration (AMD), kidney disease, and various haematological conditions. According to Rafiq Hasan, CEO and managing director at Complement Therapeutics GmbH, "the support of this broad syndicate enables us to generate additional data demonstrating CTx001's unique and differentiated mechanism of action, with the potential to transform the treatment landscape in [GA]" (9). According to the US National Eye Institute (NEI), dry AMD has three stages: early, intermediate, and late, with the disease usually progressing slowly over several years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of complement therapeutics is likely to expand further with the market poised to witness steady growth over the coming years.</description><identifier>ISSN: 1753-7967</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Atrophy ; Competition ; Disease ; Funding ; Immune system ; Innovations ; Laboratories ; Macular degeneration ; Patients ; Pharmaceutical industry ; Precision medicine ; R&amp;D ; Research &amp; development</subject><ispartof>Pharmaceutical technology Europe, 2023-07, Vol.35 (7), p.11-12</ispartof><rights>Copyright MultiMedia Healthcare Inc. Jul 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Piachaud-Moustakis, Bianca</creatorcontrib><title>Frontrunner in Therapies for Complement- Mediated Diseases</title><title>Pharmaceutical technology Europe</title><description>Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular degeneration (AMD), kidney disease, and various haematological conditions. According to Rafiq Hasan, CEO and managing director at Complement Therapeutics GmbH, "the support of this broad syndicate enables us to generate additional data demonstrating CTx001's unique and differentiated mechanism of action, with the potential to transform the treatment landscape in [GA]" (9). According to the US National Eye Institute (NEI), dry AMD has three stages: early, intermediate, and late, with the disease usually progressing slowly over several years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of complement therapeutics is likely to expand further with the market poised to witness steady growth over the coming years.</description><subject>Atrophy</subject><subject>Competition</subject><subject>Disease</subject><subject>Funding</subject><subject>Immune system</subject><subject>Innovations</subject><subject>Laboratories</subject><subject>Macular degeneration</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Precision medicine</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><issn>1753-7967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNirEOgjAUADtoIor_0MSZBG1pxRUlLm7spAmPWAJtfa_9fxn8AKdL7m7DsrOuRKFrpXdsTzSV5SoqkbFbi95FTM4Bcut49wY0wQLx0SNv_BJmWMDFgr9gsCbCwO-WwBBQzrajmQmOPx7YqX10zbMI6D8JKPaTT-jW1F-uUkhZK6nEf9cXZsM2Ug</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Piachaud-Moustakis, Bianca</creator><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RV</scope><scope>7WY</scope><scope>7X5</scope><scope>7XB</scope><scope>883</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K60</scope><scope>K6~</scope><scope>KB0</scope><scope>L.-</scope><scope>M0F</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20230701</creationdate><title>Frontrunner in Therapies for Complement- Mediated Diseases</title><author>Piachaud-Moustakis, Bianca</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_28434496463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Atrophy</topic><topic>Competition</topic><topic>Disease</topic><topic>Funding</topic><topic>Immune system</topic><topic>Innovations</topic><topic>Laboratories</topic><topic>Macular degeneration</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Precision medicine</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Piachaud-Moustakis, Bianca</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ABI/INFORM Collection</collection><collection>Entrepreneurship Database</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade &amp; Industry (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Pharmaceutical technology Europe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Piachaud-Moustakis, Bianca</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frontrunner in Therapies for Complement- Mediated Diseases</atitle><jtitle>Pharmaceutical technology Europe</jtitle><date>2023-07-01</date><risdate>2023</risdate><volume>35</volume><issue>7</issue><spage>11</spage><epage>12</epage><pages>11-12</pages><issn>1753-7967</issn><abstract>Based on the research of the company's founders, Simon Clark, Paul Bishop, and Richard Unwin from the University of Manchester, CTx aims to develop innovative and effective therapeutics to address unmet needs in complement-mediated diseases, particularly in the fields of age-related macular degeneration (AMD), kidney disease, and various haematological conditions. According to Rafiq Hasan, CEO and managing director at Complement Therapeutics GmbH, "the support of this broad syndicate enables us to generate additional data demonstrating CTx001's unique and differentiated mechanism of action, with the potential to transform the treatment landscape in [GA]" (9). According to the US National Eye Institute (NEI), dry AMD has three stages: early, intermediate, and late, with the disease usually progressing slowly over several years. With the active involvement of big pharma players as well as new entrants, the drug development landscape of complement therapeutics is likely to expand further with the market poised to witness steady growth over the coming years.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record>
fulltext fulltext
identifier ISSN: 1753-7967
ispartof Pharmaceutical technology Europe, 2023-07, Vol.35 (7), p.11-12
issn 1753-7967
language eng
recordid cdi_proquest_journals_2843449646
source EZB-FREE-00999 freely available EZB journals; Business Source Ultimate (EBSCOHost)
subjects Atrophy
Competition
Disease
Funding
Immune system
Innovations
Laboratories
Macular degeneration
Patients
Pharmaceutical industry
Precision medicine
R&D
Research & development
title Frontrunner in Therapies for Complement- Mediated Diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-26T01%3A36%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frontrunner%20in%20Therapies%20for%20Complement-%20Mediated%20Diseases&rft.jtitle=Pharmaceutical%20technology%20Europe&rft.au=Piachaud-Moustakis,%20Bianca&rft.date=2023-07-01&rft.volume=35&rft.issue=7&rft.spage=11&rft.epage=12&rft.pages=11-12&rft.issn=1753-7967&rft_id=info:doi/&rft_dat=%3Cproquest%3E2843449646%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_28434496463%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2843449646&rft_id=info:pmid/&rfr_iscdi=true